psalexa
logo

Next Generation Antibody Therapeutics Market

Global Next-Generation Antibody Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2020

Published: August 2015
Report Code: LS10246
Available Format:
Pages: 103
Category : Biotechnology

Chapter 1. Research Scope & Methodology       

1.1 Market Definition

1.2 Market Scope

1.2.1 Global next-generation antibody therapeutics market breakdown by therapeutic area

1.2.2 Global next-generation antibody therapeutics market breakdown by technology

1.2.3 Global next-generation antibody therapeutics market breakdown by geography

1.3 Research Methodology and Sources

Chapter 2. Executive Summary

2.1 Key Findings

2.2 Research Summary

Chapter 3. Market Outlook

3.1 Introduction

3.2 Trends in the Next-generation Antibody Therapeutics Market

3.2.1 Increasing popularity of antibody-drug conjugate (ADC) technology

3.2.2 Increasing number of collaborations for R&D of next-generation antibody therapeutics

3.3 Factors Driving the Market and its Impact on Market Forecast

3.3.1 Growing prevalence of chronic diseases

3.3.2 Increasing R&D for improved products

3.3.3 Increasing healthcare expenditure 

3.3.4 Technological progressions in antibody therapeutics

3.3.5 Impact analysis of drivers on market forecast

3.4 Factors Hindering the Market and its Impact on Market Forecast

3.4.1 High cost of next-generation antibody therapeutics 

3.4.2 Stringent regulatory requirements and time-consuming approval process for new drugs

3.4.3 Impact analysis of restraints on market forecast

Chapter 4. Next-Generation Antibody Therapeutics Drug Pipeline Analysis

4.1 Next-Generation Antibody Therapeutics Under Development

Chapter 5. Global Market Size and Forecast (2014 – 2020)

5.1 Global Next-Generation Antibody Therapeutics Market Breakdown by Therapeutic Area

5.2 Global Next-Generation Antibody Therapeutics Market Breakdown by Technology

5.3 Global Next-Generation Antibody Therapeutics Market Breakdown by Region

Chapter 6. Next-Generation Antibody Therapeutics Market Breakdown by Therapeutic Area

6.1 Oncology Next-Generation Antibody Therapeutics Market

6.2 Autoimmune/Inflammatory Next-Generation Antibody Therapeutics Market

Chapter 7. Next-Generation Antibody Therapeutics Market Breakdown by Technology

7.1 Antibody-Drug Conjugates (ADCs) Market

7.2 Bispecific Antibodies Market

7.3 Fc-engineered Antibodies Market

7.4 Antibody Fragments and Antibody-like Proteins Market

7.5 Biosimilar Antibody Products Market

Chapter 8. Next-Generation Antibody Therapeutics Market Breakdown by Geography

8.1 North America Next-Generation Antibody Therapeutics Market

8.1.1 North America next-generation antibody therapeutics market breakdown by country

8.1.2 North America next-generation antibody therapeutics market breakdown by therapeutic area

8.1.3 North America next-generation antibody therapeutics market breakdown by technology

8.2 Europe Next-Generation Antibody Therapeutics Market

8.2.1 Europe next-generation antibody therapeutics market breakdown by country

8.2.2 Europe next-generation antibody therapeutics market breakdown by therapeutic area

8.2.3 Europe next-generation antibody therapeutics market breakdown by technology

8.3 Asia-Pacific Next-Generation Antibody Therapeutics Market

8.3.1 Asia-Pacific next-generation antibody therapeutics market breakdown by country

8.3.2 Asia-Pacific next-generation antibody therapeutics market breakdown by therapeutic area

8.3.3 Asia-Pacific next-generation antibody therapeutics market breakdown by technology

8.4 Rest of the World Next-Generation Antibody Therapeutics Market

8.4.1 Rest of the World next-generation antibody therapeutics market breakdown by therapeutic area

8.4.2 Rest of the World next-generation antibody therapeutics market breakdown by technology 

Chapter 9. Competitive Positioning and Market Share Analysis

9.1 Porter's Five Forces of Competitive Position Analysis

9.1.1 Bargaining power of buyers

9.1.2 Bargaining power of suppliers

9.1.3 Threat of new entrants

9.1.4 Intensity of rivalry

9.1.5 Threat of substitutes      

9.2 Global Next-Generation Antibody Therapeutics Market Share, By Company

9.3 Competitive Positioning of Key Players in the Next-Generation Antibody Therapeutics Market          

Chapter 10. Company Profiles

10.1 Key Company Profiles

10.1.1 F. Hoffmann-La Roche Ltd.

10.1.1.1 Business overview

10.1.1.2 Product and service offerings

10.1.2 Kyowa Hakko Kirin Co. Ltd.

10.1.2.1 Business overview

10.1.2.2 Product and service offerings

10.1.3 Seattle Genetics Inc.

10.1.3.1 Business overview

10.1.3.2 Product and service offerings

10.1.4 ImmunoGen Inc.

10.1.4.1 Business overview

10.1.4.2 Product and service offerings

10.1.5 Bristol-Myers Squibb Company

10.1.5.1 Business overview

10.1.5.2 Product and service offerings

10.1.6 Pfizer Inc.

10.1.6.1 Business overview

10.1.6.2 Product and service offerings

10.1.7 Amgen Inc.

10.1.7.1 Business overview

10.1.7.2 Product and service offerings

10.1.8 Biogen

10.1.8.1 Business overview

10.1.8.2 Product and service offerings

10.1.9 Bayer AG

10.1.9.1 Business overview

10.1.9.2 Product and service offerings

10.1.10  Xencor Inc. 

10.1.10.1 Business overview

10.1.10.2 Product and service offerings

10.1.11  Takeda Pharmaceuticals Company Limited

10.1.11.1 Business overview

10.1.11.2 Product and service offerings

10.1.12  AstraZeneca PLC

10.1.12.1 Business overview

10.1.12.2 Product and service offerings

10.1.13  Dyax Corp.

10.1.13.1 Business overview

10.1.13.2 Product and service offerings

10.2 Strategic Developments in the Next-Generation Antibody Therapeutics Market

10.2.1 Mergers & acquisitions

10.2.2 Collaborations and partnerships

10.2.3 Product launches/ approval

Chapter 11. Appendix

11.1 List of Abbreviations

 

LIST OF TABLES

TABLE 1 SPECIFIC PRIMARY AND SECONDARY SOURCES USED FOR THIS PUBLICATION

TABLE 2 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SNAPSHOT (2014, 2015, AND 2020)

TABLE 3 DRIVERS FOR THE MARKET: IMPACT ANALYSIS

TABLE 4 ESTIMATED AVERAGE TIMELINE FOR CLINICAL TRIAL APPROVAL IN VARIOUS COUNTRIES

TABLE 5 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

TABLE 6 MAJOR NEXT-GENERATION ANTIBODY THERAPEUTICS DRUG PIPELINE

TABLE 7 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY THERAPEUTIC AREA, $M (2014 – 2020)

TABLE 8 LOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY TECHNOLOGY, $M (2014 – 2020)

TABLE 9 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY REGION, $M (2014 – 2020)

TABLE 10 GLOBAL ONCOLOGY NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY REGION, $M (2014 – 2020)

TABLE 11 GLOBAL AUTOIMMUNE/INFLAMMATORY NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY REGION, $M (2014 – 2020)

TABLE 12 GLOBAL ANTIBODY DRUG CONJUGATES MARKET BREAKDOWN BY REGION, $M (2014 – 2020)

TABLE 13 GLOBAL BISPECIFIC ANTIBODIES MARKET BREAKDOWN BY REGION, $M (2014 – 2020)

TABLE 14 GLOBAL FC ENGINEERED ANTIBODIES MARKET BREAKDOWN BY REGION, $M (2014 – 2020)  

TABLE 15 GLOBAL ANTIBODY FRAGMENTS AND ANTIBODY-LIKE PROTEINS MARKET BREAKDOWN BY REGION, $M (2014 – 2020)

TABLE 16 GLOBAL BIOSIMILARS ANTIBODY PRODUCTS MARKET BREAKDOWN BY REGION, $M (2014 – 2020)

TABLE 17 NORTH AMERICA NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY COUNTRY, $M (2014 – 2020)

TABLE 18 NORTH AMERICA NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY THERAPEUTIC AREA $M (2014 – 2020)

TABLE 19 NORTH AMERICA NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY TECHNOLOGY, $M (2014 – 2020)

TABLE 20 EUROPE NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY COUNTRY, $M (2014 – 2020)

TABLE 21 EUROPE NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY THERAPEUTIC AREA $M (2014 – 2020)

TABLE 22 EUROPE NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY TECHNOLOGY, $M (2014 – 2020)

TABLE 23 ASIA-PACIFIC NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY COUNTRY, $M (2014 – 2020)

TABLE 24 ASIA-PACIFIC NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY THERAPEUTIC AREA, $M (2014 – 2020)

TABLE 25 ASIA-PACIFIC NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY TECHNOLOGY, $M (2014 – 2020)

TABLE 26 REST OF THE WORLD NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY THERAPEUTIC AREA, $M (2014 – 2020)

TABLE 27 REST OF THE WORLD NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET BREAKDOWN BY TECHNOLOGY, $M (2014 – 2020)

TABLE 28 F. HOFFMANN-LA ROCHE LTD – KEY FACTS

TABLE 29 KYOWA HAKKO KIRIN CO. LTD. – KEY FACTS

TABLE 30 SEATTLE GENETICS INC. – KEY FACTS

TABLE 31 IMMUNOGEN INC. – KEY FACTS

TABLE 32 BRISTOL-MYERS SQUIBB COMPANY – KEY FACTS

TABLE 33 PFIZER INC.– KEY FACTS

TABLE 34 AMGEN INC. – KEY FACTS

TABLE 35 BIOGEN – KEY FACTS

TABLE 36 BAYER AG – KEY FACTS

TABLE 37 XENCOR, INC. – KEY FACTS

TABLE 38 TAKEDA PHAXRMACEUTICALS COMPANY LIMITED. – KEY FACTS

TABLE 39 ASTRAZENECA PLC. – KEY FACTS

TABLE 40 DYAX CORP. – KEY FACTS

 

LIST OF FIGURES

FIG 1 RESEARCH SCOPE FOR GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET   

FIG 2 RESEARCH METHODOLOGY FOR GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET

FIG 3 HEALTH EXPENDITURE AS PERCENTAGE OF GDP (2002 AND 2012)

FIG 4 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, $M (2014 – 2020)

FIG 5 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY THERAPEUTIC AREA (2014 AND 2020)

FIG 6 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TECHNOLOGY $M (2014 – 2020)

FIG 7 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY TECHNOLOGY (2014 AND 2020)

FIG 8 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, $M (2014 – 2020)

FIG 9 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 10 GLOBAL ONCOLOGY NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SIZE BY REGION, $M (2014 - 2020)

FIG 11 GLOBAL ONCOLOGY NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 12 GLOBAL AUTOIMMUNE/INFLAMMATORY NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SIZE BY REGION, $M (2014 – 2020)

FIG 13 GLOBAL AUTOIMMUNE/INFLAMMATORY NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 14 GLOBAL ANTIBODY DRUG CONJUGATES MARKET SIZE BY REGION, $M (2014 – 2020)

FIG 15 GLOBAL ANTIBODY DRUG CONJUGATES MARKET SHARE, BY REGION (2014 AND 2020)

FIG 16 GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE BY REGION, $M (2014-2020)

FIG 17 GLOBAL BISPECIFIC ANTIBODIES MARKET SHARE, BY REGION (2014 AND 2020)

FIG 18 GLOBAL FC ENGINEERED ANTIBODIES MARKET SIZE BY REGION, $M (2014 – 2020)

FIG 19 GLOBAL FC ENGINEERED ANTIBODIES MARKET SHARE, BY REGION (2014 AND 2020)

FIG 20 GLOBAL ANTIBODY FRAGMENTS AND ANTIBODY-LIKE PROTEINS MARKET SIZE BY REGION, $M (2014 - 2020)

FIG 21 GLOBAL ANTIBODY FRAGMENTS AND ANTIBODY-LIKE PROTEINS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 22 GLOBAL BIOSIMILARS ANTIBODY PRODUCTS MARKET SIZE BY REGION, $M (2014 – 2020)

FIG 23 GLOBAL BIOSIMILARS ANTIBODY PRODUCTS MARKET SHARE, BY REGION (2014 AND 2020)

FIG 24 GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET, BY GEOGRAPHY (2020)

FIG 25 NORTH AMERICA NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SIZE BY COUNTRY, $M (2014 – 2020)

FIG 26 NORTH AMERICA NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY COUNTRY (2014 AND 2020)

FIG 27 NORTH AMERICA NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA $M (2014 – 2020)

FIG 28 NORTH AMERICA NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY THERAPEUTIC AREA (2014 AND 2020)

FIG 29 NORTH AMERICA NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TECHNOLOGY $M (2014 – 2020)     

FIG 30 NORTH AMERICA NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY TECHNOLOGY (2014 AND 2020)

FIG 31 EUROPE NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SIZE BY COUNTRY, $M (2014-2020)

FIG 32 EUROPE NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY COUNTRY (2014 AND 2020)

FIG 33 EUROPE NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA $M (2014 – 2020)

FIG 34 EUROPE NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY THERAPEUTIC AREA (2014 AND 2020)

FIG 35 EUROPE NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SIZE, BY TECHNOLOGY $M (2014 – 2020)

FIG 36 EUROPE NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY TECHNOLOGY (2014 AND 2020)

FIG 37 ASIA-PACIFIC NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SIZE BY COUNTRY, $M (2014-2020)        

FIG 38 ASIA-PACIFIC NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY COUNTRY (2014 AND 2020)

FIG 39 ASIA-PACIFIC NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SIZE BY THERAPEUTIC AREA, $M (2014 – 2020)

FIG 40 ASIA-PACIFIC NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY THERAPEUTIC AREA (2014 AND 2020)

FIG 41 ASIA-PACIFIC NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SIZE BY TECHNOLOGY, $M (2014 – 2020)

FIG 42 ASIA-PACIFIC NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SHARE, BY TECHNOLOGY (2014 AND 2020)

FIG 43 REST OF THE WORLD NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SIZE BY THERAPEUTIC AREA, $M (2014 – 2020)

FIG 44 REST OF THE WORLD NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET SIZE BY TECHNOLOGY, $M (2014 – 2020)   

FIG 45 PORTER’S FIVE FORCES OF COMPETITIVE POSITION ANALYSIS

FIG 46 MARKET SHARE OF KEY PLAYERS IN THE GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET (2014)

FIG 47 COMPETITIVE POSITIONING OF KEY PLAYERS IN THE GLOBAL NEXT-GENERATION ANTIBODY THERAPEUTICS MARKET (2014)

 

 

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry